Global group exploits US biotechnologies to accelerate work on Nipah vaccine

LONDON (Reuters) – A global coalition created a year ago to fight epidemics reached a $ 25 million agreement with two US biotechnology companies to speed up work on a vaccine against the Nipah virus that has caused the death of At least 11 people In India.

Doctors wearing protective equipment examine a patient in a hospital in Kozhikode in the southern state of Kerala, India on May 21, 2018. REUTERS / Stringer

The Coalition for Epidemic Preparation Innovations said on Thursday that Profectus BioSciences and Emergent BioSolutions receive up to $ 25 million to advance the development and manufacture of a vaccine against the disease transmitted by bats.

Currently there is no vaccine for Nipah.

The death toll from the latest outbreak in Kerala rose to 11 on Wednesday, while Indian health officials said they were monitoring two suspected cases in the neighboring state of Karnataka.

Information of Ben Hirschler; Editing by Edmund Blair


Source link